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Background: Previous studies have described expenditures for antiretroviral (ARV) medicines in Brazil through 2005.
While prior studies examined overall expenditures, they have not have analyzed drug procurement data in order to
describe the role of court litigation on access and pricing.
Methods: ARV drug procurement from private sector sources for the years 2004–2011 was obtained through the
general procurement database of the Brazilian Federal Government (SIASG). Procurement was measured in Defined
Daily Doses (DDD) per 1000 persons-under-treatment per day. Expenditures and price per DDD were calculated and
expressed in U.S. Dollars. Justifications for ARV purchases were examined in order to determine the relationship
between health litigation and incorporation into Brazil’s national treatment guidelines.
Results: Drug procurement of ARVs from private sources underwent marked expansion in 2005, peaked in 2009,
and stabilized to 2008 levels by 2011. Expenditures followed procurement curves. Medications which were procured
for the first time after 2007 cost more than medicines which were introduced before 2007. Judicial actions initially
resulted in purchases of newer medications for a select number of patients in Brazil but ultimately expanded
availability to a larger population through incorporation into the national treatment guidelines.
Conclusions: Drug procurement and expenditures for ARVs in Brazil varied between 2004–2011. The procurement
of some drugs from the private sector ceased after public manufacturers started producing them locally. Judicial
demand has resulted in the incorporation of newer drugs into the national treatment guidelines. In order for the
AIDS treatment program to remain sustainable, efforts should be pursued to reduce prices through generic drugs,
price negotiation and other public health flexibilities such as compulsory licensing.
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Brazil is a middle-income country that has officially pro-
vided universal access to anti-retroviral treatment since
1996 [1]. In what has become known as the “Brazilian
Model,” the national AIDS program simultaneously bal-
anced the need for expanded access with the needs of
program sustainability [2-4]. Although patents for phar-
maceutical products have been granted since 1997, au-
thorities have been able to utilize public health flexibilities
in order to decrease costs associated with treatment [5,6].* Correspondence: claudia.osorio@ensp.fiocruz.br
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reproduction in any medium, provided the orFor example, between 2000 and 2004, overall expenditures
for antiretroviral medications (ARVs) decreased, despite
an increase in the number of people receiving ARVs. This
was mostly due to generic competition, negotiated price
reductions with originator companies, and domestic pro-
duction through Brazil’s public drug manufacturers [7].
However, by 2005, changes to first and second line treat-
ment guidelines and the introduction of newer, patented
medicines led to an increase in expenditures [8,9] and to
an upsurge in judicial demand for originator medicines
which were previously unavailable through Brazil’s na-
tional treatment guidelines. Between the years 2007 and
2009, treatment costs decreased from 2005 levels, and
remained around $1700 per patient per year [10]. In 2011,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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representing an estimated ART coverage of 72% [11].
Using the rhetoric of human rights and anti-
discrimination, civil society groups in Brazil have been
instrumental in advancing the access agenda [12]. A
compulsory license was issued for efavirenz in 2007,
which reduced treatment expenditures by approxi-
mately $103.6 million [13]. Gilead’s initial patent for
tenofovir was rejected after civil society groups filed a
successful pre-grant opposition [14]. Patient advocacy
groups have also been successful in using Brazilian
courts to win access to new, previously unavailable
medications [15].
Due to administrative changes, official data on expen-
ditures for AIDS treatment has not been easily access-
ible. Since the 2011 passage of an access to information
law (No. 12.527), alternate sources of government pro-
curement data have become available. The objective of
our study was to describe the evolution of private sector
ARV procurement and expenditures from 2004–2011
using data from the federal government. We also de-
scribe judicial actions for newer ARVs, examining their
results on increased availability.
Methods
ARV drug procurement from the private sector for the
years 2004–2011 was obtained from the Sistema Inte-
grado de Administração de Serviços Gerais (SIASG), the
general procurement database of the Brazilian federal
government. The SIASG data is publically available;
however availability is subject to data extraction by the
Department of Health Economics, Investment, and De-
velopment at the Ministry of Health. This database in-
cludes only purchases from the private sources (both
national and international suppliers), and does not in-
clude medicines procured from local public manufactu-
rers such as Farmanguinhos. Filters were used to select
data specific to the Ministry of Health and the Logistics
Department (who is solely responsible for purchases for
all ARVs). A comprehensive list of all purchases of ARVs
from the private sector was thus obtained for each year.
Information was obtained for the following variables:
name of drug, dosage form and concentration, quantity,
unit price, date of purchase, justification for purchase
and method of tender.
ARVs were then classified by means of the WHO
Anatomical Therapeutic Chemical Classification System
(ATC) and their Defined Daily Doses (DDD) obtained
[16,17]. In order to make this unit of measurement more
adequate for the description of ARV procurement, the
number of DDDs was calculated for each ARV and the
results expressed as the number of DDDs/1000 persons-
under-treatment/day. We chose to express volume pro-
cured in this manner because it reflects the extent towhich procurement from private sector sources satisfies
demand for ARVs in Brazil. Data on volumes and ex-
penditures from public sector procurement was not
available due to the nature of the SIASG database. The
number of patients on treatment nationally was obtained
from the MonitorAIDS website for the years 2004–2010
[18]. The number of people on treatment in 2011 was
obtained from the national program for STD/AIDS (per-
sonal communication).
Subgroup analyses also included collapsing the ARV
ATC codes to map procurement over time according to
antiretroviral treatment class. The justification for each
ARV purchase was examined in order to determine the
dynamics of purchases in relation to health litigation.
We then plotted the number of purchases which re-
sulted from court cases over time and compared these
actions with both bulk purchases and the dates of in-
corporation of each medicine into the national treatment
guidelines [19].
We expressed prices of individual drugs using price
per DDD (in U.S. Dollars). The price per DDD is a bet-
ter approximation of treatment prices than price per
tablet because the DDD is based on the average adult
daily dose. To calculate price per DDD, we summed
each ARV in grams and then divided that sum by the
listed DDD for the particular drug to obtain the total
number of DDDs purchased. We then divided the total
amount spent for that drug in a given year by the total
number of DDDs to obtain price per DDD.
We show individual drug pricing for select ARVs only
from 2007 onwards because many novel ARVs were not
procured in Brazil prior to 2007, making it difficult to
compare prices of ARVs from 2004 to 2007. Further-
more, 2007 was a landmark year in Brazil’s national treat-
ment program because of the issuance of a compulsory
license for efavirenz.
Calculations and graphs were made with the help of
Excel (Microsoft Corp. 2010). Expenditures were calcu-
lated by multiplying unit price by volume purchased.
Costs were expressed in U.S. Dollars using mean annual
exchange rates provided by the U.S. Federal Reserve
Bank [20].
Results
Overall, our database of ARVs included 21 different me-
dications in 40 dosage forms. There were only two fixed
dose combination ARV medications: lopinavir/ritonavir
and zidovudine/lamivudine. Individual purchases ranged
from as few as three units (tipranavir in 2006) to as
many as 106,080,000 units (lopinavir 200 mg/ritonavir
50 mg in 2011). The results of our descriptive ana-
lysis of the SIASG database are shown in Figure 1.
This figure shows drug procurement from the private
sector expressed in number of DDDs/1000 persons-
Figure 1 Drug Procurement and total expenditures for antiretroviral medicines in Brazil from 2004–2011. Volume procured expressed as
DDD/1000 persons-under-treatment/day.
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class. It also shows annual federal expenditures for pri-
vately procured ARVs in U.S. dollars from 2004 – 2011.
Procurement in DDDs per 1000 persons under treatment
per day
Overall drug procurement rose dramatically from a
low of 124 DDDs/1000 persons-under-treatment/day in
2004 to 929 DDDs/1000 persons-under-treatment/day
in 2005. While procurement from the private sector in-
volved all three major classes: nucleoside reverse tran-
scriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), and protease inhibi-
tors (PIs) from the years 2004 until 2006, by 2007 the
procurement of NNRTIs fell drastically and PIs became
the predominant class of medications procured from the
private sector by the federal government. This trend
continued in subsequent years (with the exception of
2008, where a large purchase of tenofovir resulted in
higher number of DDDs/1000 persons-under-treatment/
day of NRTIs when compared to PIs). In 2008, the
government began to procure newer classes of drugs
such as integrase inhibitors (raltegravir), entry inhibitors
(maraviroc) and fusion inhibitors (enfurvitide). In 2010,
there was a significant reduction in overall drug pro-
curement from the private sector (from 1534 DDDs/
1000 persons-under-treatment/day to 238 DDDs/1000
persons-under-treatment/day), which was likely due to
the fact that some intensively purchased or expensive
medications such as lopinavir/ritonavir and darunavir
were possibly procured in excess quantities during the
previous year in order to cover the needs of the national
treatment program for a two year span (data not shown).
Additionally, the NRTI tenofovir (which represented thevast majority of NRTIs utilized in prior years) was not
purchased from the private sector in either 2010 or 2011
due to domestic production in Brazil’s national public
laboratories.
In 2004, the predominant PI procured was saquinavir.
In 2005 and 2006, the most frequently procured PIs were
atazanavir (362 DDDs/1000 persons-under-treatment/
day) and nelfinavir (14 DDDs/1000 persons-under-
treatment/day). In 2007, lopinavir/ritonavir became pre-
dominant PI (306 DDDs/1000 persons-under-treatment/
day). This was also the case for the years 2009 and 2011.
On alternating years (2008 and 2010), atazanavir was the
most frequently procured PI.
Expenditures
The curve of federal expenditures follows that of drug
procurement (Figure 1). Overall federal expenditures for
private sector ARV procurement more than doubled
from $114 million dollars in 2004 to $287 million dollars
in 2005. Expenditures then came down slowly over the
next three years (with a low of $176 million dollars in
2007). In 2009, federal expenditures for ARVs again dou-
bled to reach a high of $375 million dollars before falling
to $69 million dollars in 2010. In 2011, expenditures
returned to 2006 levels ($262 million dollars).
Pricing
In general, between 2007 to 2011, the price of medica-
tions per DDD were higher for drugs which were added
to Brazil’s national treatment guidelines more recently
when compared to older ARVs (see Table 1). For ex-
ample, on average, medications which were introduced
prior to 2007 (e.g. didanosine, saquinavir) had price per
DDD ranging from $1.55 to $7.98. Medications procured
Table 1 Price per DDD for selected ARVs between 2007
and 2011
2007 2008 2009 2010 2011 Average
Abacavir 4.62 2.94 3.78
Didanosine 1.54 1.73 1.51 1.41 1.55
Nelfinavir 4.38 4.38
Saquinavir 7.20 7.80 8.23 8.68 7.98
Atazanavir 3.51 4.13 4.86 3.92 3.11 3.91
Lopinavir/ritonavir 2.79 2.92 2.31 2.67
Darunavir 19.79 19.92 15.86 16.60 18.04
Etravirine 30.95 22.72 22.96 25.54
Raltegravir 21.31 18.48 16.85 18.88
Maraviroc 25.27 29.90 37.00 39.90 33.02
All values expressed as $U.S. Dollars.
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price per DDD ranges between $18.88 and $33.02.
Some medications experienced significant price re-
ductions over time. For example, Brazil paid $80.06 per
DDD for lopinavir 133 mg/ritonavir 33.3 mg capsules in
2004. By 2011, the government of Brazil purchased only
the 200 mg/50 mg heat-stable formulation of lopinavir/
ritonavir at a cost of $2.31 per DDD. While the exact ra-
tionale for this thirty-fold reduction in price per DDD
cannot be derived from the SIASG database, our hypothe-
sis is that Brazil’s involvement in an international move-
ment demanding access to ARVs and the threat of a
compulsory license for lopinavir/ritonavir allowed the
Ministry of Health to negotiate significant price reductions
for this medication with Abbott Laboratories [5].Figure 2 Number of purchases of selected antiretroviral medications
indicate the approximate time when each medication was incorporated inExpanding access to treatment, the relationship between
judicial action and incorporation into national treatment
guidelines
Figure 2 shows the number of purchases per year of four
medications (darunavir, etravirine, raltegravir and mara-
viroc) based on the justification of judicial action. As
demonstrated, the overall number of judicial actions in-
creased from 2007 to 2011, with a high in 2008 of 35 ju-
dicial actions resulting in ARV purchases.
A higher number of judicial actions for a drug made
it more likely for that drug to be subsequently in-
corporated into the national treatment guidelines. For
example, there were 20 judicial actions in 2007 for daru-
navir between January 7th and December 31st resulting
in the purchase of 13,200 units of the drug. Darunavir
was added to the treatment guidelines in October 2007.
On December 26th, shortly after incorporation, the gov-
ernment purchased 2.28 million units of darunavir. After
a drug was added to the treatment guidelines, judicial
demand falls dramatically. For example, there was only
one darunavir purchase due to judicial action in the
years following its incorporation. This trend continued
for all other ARVs in the database.
There were only 6 judicial actions for raltegravir in 2009.
However, in the year prior to its incorporation, there were
23 judicial actions resulting in 9,360 units purchased. On
November 18th, 2008 there was a purchase of 720,000 units
of raltegravir, likely in anticipation of its official incorpor-
ation into the consensus guidelines by January 2009.
There were 5 judicial actions in 2010 for etravirine
resulting 3,240 units purchased. Etravirine was incorpo-
rated into the treatment guidelines on October 2010. Onas a result of judicial action, from 2007–2011. Colored arrows
to Brazil’s national treatment guideline.
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of etravirine.
From 2009 to 2011, there were over 20 judicial actions
each year resulting in purchases of maraviroc. In 2011,
there were 29 judicial actions for maraviroc resulting in
the purchase of 24,600 units of maraviroc. This medica-
tion was not included until the most recent supplement
to the treatment guidelines (July 2012).
Discussion
Our study is the first of its kind in Brazil which describes
private sector ARV drug procurement from the years
2004–2011. Previous studies used expenditure data pro-
vided from the national AIDS program, but were from
analysis which did not include line-item data such as
price per unit, or justification for purchase. Thus, while
prior studies estimated contracted demand, ours reflects
actual procurement. Additionally, we were able to exam-
ine the effect of litigation on the procurement of newer
medications and incorporation into the national treat-
ment guidelines. Our work increases the understanding
of Brazil’s evolving national AIDS treatment program,
which was founded on the principles of universal access
[12,21].
Implications for pricing and sustainability
Our results show that the pricing of drugs has not
remained stable. Medicines which were introduced at
very high prices such as and lopinavir/ritonavir achieved
significant price reductions over time. In general, ARVs
first introduced in Brazil after 2007 cost significantly
more per DDD than ARVs introduced prior to 2007.
Our results suggest that the government of Brazil
should be prepared for a trend towards the use of newer,
more expensive medications. Although these newer
medications are reserved for cases of treatment failure
or for salvage regimens, the fact that the AIDS popula-
tion in Brazil is one of the oldest treatment cohorts
among developing countries suggest that newer medi-
cines will be needed. Our results indicate a trend to-
wards growth in the procurement of fusion inhibitors,
integrase inhibitors and newer PIs which have no gen-
eric competition. As such, in order for the program to
remain sustainable, efforts should be aggressively pur-
sued to reduce prices through price negotiation, exercis-
ing TRIPS flexibilities and local production [22].
Results of Judicial Action
Our results indicate that the number of judicial actions
is related to timing of incorporation into Brazil’s national
treatment guidelines. With the exception of etravirine
(which was incorporated after published data showed
improved outcomes for treatment-experienced patients),
the government of Brazil usually timed its purchases oflarge quantities of newer ARVs following the results of
numerous court cases, often greater than 20 a year, in
favor of plaintiffs [23]. Shortly after these large purchases
by the Ministry of Health, the medication was incorpo-
rated into the following years’ treatment guidelines.
These results suggest one of three possibilities: 1) the
relationship between number of judicial actions and tim-
ing of incorporation into the national treatment guide-
line is coincidental (unlikely), 2) judicial demand is a
reflection of established treatment preferences by pre-
scribers (which prompts review by the expert commit-
tees who meet annually to draft treatment guidelines), or
3) judicial action may exert a previously undescribed de-
gree of influence on a process which is presumed to be
objective and evidence-based.
Our work supports previous literature which has de-
scribed the impact of litigation for access to medicines
[24-27]. While many have suggested that drug compan-
ies may be using patient advocacy groups to expand
market share through litigation, our study is the first
which directly examines the impact of judicial cases on
national drug procurement [28]. Overall, our results in-
dicate that judicial demand has been highly successful in
granting access to newer ARVs.Strengths and Limitations
One of the strengths of our study was that we were able
to monitor trends in expenditures for private sector pur-
chases of ARVs by the federal government. These medi-
cations often account for the bulk of expenditures for
AIDS treatment because they are patented, and have little
or no available competitors in the national or international
market. Additionally, this type of drug procurement may
be a proxy for measuring external dependency in the med-
icines market as all recorded drugs were purchased either
directly from foreign suppliers, or from domestic private
pharmaceutical companies operating under licensing ag-
reements with foreign companies. Another strength is that
our data is extracted from only one ministry located in the
global South, and does not include figures from inter-
national sources such as the Global Fund, PEPFAR, or
Clinton Health Access Initiative [29].
Limitations of our study include the fact that we could
only describe one measure of drug utilization (procure-
ment), and did not have access to other measures such
as number of prescriptions or level of consumption. We
could not describe relative use of drug classes in the
population directly because we did not have access to
treatment data. Additionally, because the SIASG data-
base does not include public domestic production, we
could not estimate overall ARV procurement as a proxy
of drug utilization for the entire country. However, we
did validate our data by comparing our expenditures
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tional AIDS program.
Future Studies
Our work opens the possibilities for many future studies.
For example, the SIASG database could be examined to
compare prices paid with patent status of medications in
Brazil [30]. Additionally, if this data could be combined
with drug procurement measures from public national
manufacturers and drug prescribing and dispensing (a
proxy to consumption), a correlation would be shown
between increased drug utilization and improved clinical
outcomes such as decreased AIDS morbidity/mortality
and reduced transmission. Another study could further
explore the causes for lopinavir/ritonavir’s thirty-fold re-
duction in price from 2004 to 2007.
Conclusions
Drug procurement and expenditures for private sector
ARVs in Brazil varied between 2004–2011. ARVs which
were procured for the first time after 2007 cost more
than medications which were introduced prior to 2007.
Judicial demand has resulted in the procurement of large
quantities of newer, more expensive medications through
incorporation into the national treatment guidelines. Our
study suggests that recent judicial actions may have an im-
pact on program sustainability. In order for the AIDS
treatment program to remain sustainable, efforts should
be pursued to reduce prices through price negotiation and
other public health flexibilities.
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